Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of $3.42. Earnings rose 17% year over year on a reported basis, boosted by ...

SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps an Outperform rating on the shares. The firm’s ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Biogen reported fourth-quarter 2024 earnings that surpassed analysts' expectations, driven by strong sales of new product ...

H.C. Wainwright analyst Douglas Tsao revised the price target for Sage Therapeutics (NASDAQ:SAGE) to $12.00 from the previous $14.00 while maintaining a Neutral rating on the company's shares. Tsao's ...

Canaccord lowered the firm’s price target on Sage Therapeutics (SAGE) to $8 from $9 and keeps a Hold rating on the shares. The firm said they ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "We ...

Analysts expect the Cambridge, Massachusetts-based company to report quarterly earnings at $3.36 per share, up from $2.95 per ...